Urokinase is required for the formation of mactinin, an α-actinin fragment that promotes monocyte/macrophage maturation

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1591, Issue 1-3, 2002, Pages 99-107

  Luikart, Sharon ^a   Masri, Mohammed ^a,b   Wahl, Dan ^a   Hinkel, Tim ^a   Beck, James M ^c   Gyetko, Margaret R ^c   Gupta, Pankaj ^a,b   Oegema, Theodore ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Actinin; Monocyte; Urokinase

Indexed keywords

ALPHA ACTININ; AMILORIDE; BENZYLSULFONYL FLUORIDE; CYSTEINE PROTEINASE INHIBITOR; ENZYME INHIBITOR; IODINE 125; METALLOPROTEINASE INHIBITOR; PLASMIN; PROTEIN; PROTEIN MACTININ; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CELL FUNCTION; CELL LINE; CELL LYSATE; CELL MATURATION; CONTROLLED STUDY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LUNG LAVAGE; MACROPHAGE; MOLECULAR WEIGHT; MONOCYTE; NORMAL HUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; WILD TYPE;

ACTININ; AMILORIDE; ANIMALS; CELL AGING; ENVIRONMENT; HL-60 CELLS; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; MOLECULAR WEIGHT; MONOCYTES; PEPTIDE FRAGMENTS; SERINE PROTEINASE INHIBITORS; TOSYL COMPOUNDS; URINARY PLASMINOGEN ACTIVATOR;

PNEUMOCYSTIS CARINII;

EID: 0037135696     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(02)00255-0     Document Type: Article

References (64)

1. Mayani H., Guilbert L.J., Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. Eur. J. Haematol. 49:1992;225-233.
2. Minden M. Growth factor requirements for normal and leukemic cells. Semin. Hematol. 32:1995;162-182.
3. Verfaillie C., Hurley R., Bhatia R., McCarthy J.B. Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit. Rev. Oncol./Hematol. 16:1994;201-224.
4. Janowska-Wieczorek A., Marquez L.A., Matsuzaki A., Hashmi H.R., Larratt L.M., Boshkov L.M., Turner A.R., Zhang M.C., Edwards D.R., Kossakowska A.E. Expression of matrix metalloproteinass (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 105:1999;402-411.
5. Altieri D.C. Proteases and protease receptors in modulation of leukocyte effector functions. J. Leukoc. Biol. 58:1995;120-127.
6. Luikart S.D., Wahl D., Hinkel T., Masri M., Oegema T. A fragment of α-actinin promotes monocyte/macrophage maturation in vitro. Exp. Hematol. 27:1999;337-344.
7. Immura M., Masaki T. Identification of 115 kDa protein from muscle tissues: expression of a novel non-muscle α-actinin in vascular endothelial cells. Exp. Cell Res. 211:1994;380-390.
8. Duhaiman A.S., Bamburg J.R. Isolation of brain α-actinin. Its characterization and comparison of its properties with those of muscle α-actinins. Biochemistry. 23:1984;1600-1608.
9. Koboyashi R., Tashima Y. Purification and characterization of an α-actinin-like protein from porcine kidney. Biochim. Biophys. Acta. 745:1983;209-216.
10. Burridge K., Fath K., Kelly T., Nuckolls G., Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu. Rev. Cell Biol. 4:1988;487-525.
11. Lark L.W., Laterra J., Culp L.A. Close and focal contact adhesions of fibroblasts to a fibronectin-containing matrix. Fed. Proc. 44:1985;394-403.
12. Masri M.T., Wahl D., Oegama T., Luikart S.D. HL-60 cells degrade α-actinin to produce a fragment that promotes monocyte/macrophage maturation. Exp. Hematol. 27:1999;345-352.
13. Lijnen H.R., Collen D. Matrix metalloproteinase system deficiencies and matrix degradation. Thromb. Haemost. 82:1999;837-845.
14. Turk B., Turk V., Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 378:1999;141-150.
15. Carmeliet P., Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. 91:1998;255-285.
16. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., DeVos R., van den Oord J.J., Collen D., Mulligan R.C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:1994;419-424.
17. Beck J.M., Preston A.M., Gyetko M.R. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice. Infect. Immun. 67:1999;879-884.
18. Luikart S.D., Sackrison J.L., Maniglia C.A. Bone marrow matrix modulation of HL-60 phenotype. Blood. 70:1987;1119-1123.
19. Gospodarowicz D., Delgado D., Vlodavsky I. Permissive effect of the extracellular matrix on cell proliferation in vitro. Proc. Natl. Acad. Sci. U. S. A. 77:1980;4094-4098.
20. Mueller J., Brun del Re G., Buerki H., Keller H.U., Hess M.W., Coltier H. Nonspecific acid esterase activity: a criterion for differentiation of T and B lymphocytes in mouse lymph nodes. Eur. J. Immunol. 5:1975;270-274.
21. Lotem J., Sachs L. Different blocks in the differentiation of myeloid leukemia cells. Proc. Natl. Acad. Sci. U. S. A. 71:1974;3507-3511.
22. Bianco C., Patrick R., Nussenzweig V. A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J. Exp. Med. 132:1970;702-720.
23. Vassalli J.D., Belin D. Amiloride selectively inhibits urokinase-type plasminogen activator. FEBS Lett. 214:1987;187-191.
24. Gyetko M.R., Chen G.H., McDonald R.A., Goodman R., Huffnagle G.B., Wilkinson C.C., Fuller J.A., Toews G.B. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: a murine transgenic model. J. Clin. Invest. 97:1996;1818-1826.
25. Nathan C.F. Secretory products of macrophages. J. Clin. Invest. 79:1987;319-326.
26. Werb Z., Banada M.J., Jones P.A. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J. Exp. Med. 152:1980;1340-1357.
27. Campbell E.J., Curry J.D., Shapiro S.D., Goldberg G.I., Welgus H.G. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J. Immunol. 146:1991;1286-1293.
28. Murphy G., Willenbrock F., Crabbe T., O'Shea M., Ward R., Atkinson S., O'Connell J., Duchorty A. Regulation of matrix metalloproteinase activity. Ann. N. Y. Acad. Sci. 732:1994;31-41.
29. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
30. Damsky C.H., Werb Z. Signal transduction by integrin receptors for extracellular matrix. Cooperative processing of extracellular information. Curr. Opin. Cell Biol. 4:1992;772-781.
31. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11:1995;549-599.
32. Mane S., Winkelmann J.C., Luikart S.D. Bone marrow extracellular matrix induces HL-60 cells to produce an autonomous differentiation factor. Cell Growth Differ. 2:1991;637-643.
33. Gyetko M.R., Shollenberger S.B., Sitrin R.G. Urokinase expression in mononuclear phagocyte cell: cytokine-specific modulation by interferon-γ and tumor necrosis factor-α J. Leukoc. Biol. 51:1992;256-263.
34. Arumugam S., Jang Y.C., Chen-Jensen C., Gibran N.S., Isik F.F. Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair. Surgery. 125:1999;587-593.
35. Khan K.M.F., Falcone D.J. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92 kDa metelloproteinase expression. J. Biol. Chem. 272:1997;8270-8275.
36. Gordon S. Regulation of enzyme secretion by mononuclear phagocytes: studies with macrophage plasminogen activators and lysozyme. Fed. Proc. 37:1978;2754-2758.
37. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44:1985;139-266.
38. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta. 823:1995;35-65.
39. Lijnen H.R., Wagner E.F., Collen D. Plasminogen-dependent and independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Thromb. Haemost. 77:1997;362-367.
40. Blasi F., Stoppell M.P., Cubellis M.V. The receptor for urokinase plasminogen activator. J. Cell. Biochem. 32:1986;179-186.
41. Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F., Associan R.K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. U. S. A. 82:1985;4939-4943.
42. Blasi F., Vassalli J.D., Dano K. Urokinase type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104:1987;801-804.
43. Blasi F. The urokinase receptor and cell migration. Semin. Thromb. Hemost. 22:1996;513-516.
44. Hearing V.J., Law L.W., Corti A., Appella E., Blasi F. Modulation of metastatic potential by cell surface urokinase murine melanoma cells. Cancer Res. 48:1988;1270-1278.
45. Ossowski L., Clunie G., Mascucci M.T., Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115:1991;1107-1112.
46. Hart P.H., Vitti G.F., Burgess D.R., Whitty G.A., Royston K., Hamilton J.A. Activation of human monocytes by granulocyte-macrophage factor: increased urokinase-type plasminogen activator activity. Blood. 77:1991;841-848.
47. Bugge T.H., Flick M.J., Danton M.J., Daugherty C.C., Romer J., Dano K., Carmeliet P., Collen D., Degen J.L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. 92:1996;5899-5904.
48. Conforti G., Dominguez-Jimenez C., Ronne E., Hoyer-Hansen G., Dejana E. Cell surface plasminogen activator causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer. Blood. 83:1994;994-1005.
49. Busso N., Masur S.K., Lazega D., Waxman S., Ossowpski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126:1994;259-270.
50. Pollanen J., Sakselo O., Salonen E.M., Andreasen P., Nielsen L., Dano K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitors under cultured human fibroblasts and sarcoma cells. J. Cell Biol. 104:1987;1085-1096.
51. Wei Y., Lukashev M., Simon D.I., Bodary C., Rosenberg S., Doyle M., Chapman H.A. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
52. Waltz D.A., Sailor L.Z., Chapman H.A. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91:1993;1541-1552.
53. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380-32388.
54. 2-integrin and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1995;1381-1390.
55. Sitrin R.G., Todd R.F., Albrecht E., Gyetko M.R. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest. 97:1996;1942-1951.
56. Marchina E., Barlati S. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase. Int. J. Biochem. Cell Biol. 28:1996;1141-1150.
57. Unkeless J.C., Gordon S., Reich E. Secretion of plasminogen activator by stimulated macrophages. J. Exp. Med. 139:1974;834-850.
58. Jones P.A., Scott-Burden T. Activated macrophages digest extracellular matrix proteins produced by cultured cells. Biochem. Biophys. Res. Commun. 86:1979;71-77.
59. Furie M.B., Rifkin D.B. Proteolytically derived fragments of human plasma fibronectin and their localization within the intact molecule. J. Biol. Chem. 255:1980;3134-3140.
60. Homandberg G.A., Meyers R., Xie D. Fibronectin fragments cause chrondrolysis of bovine articular cartilage slices in culture. J. Biol. Chem. 267:1992;3597-3604.
61. Moser T.L., Enghild J.J., Pizzo S.V., Stack M.S. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J. Biol. Chem. 268:1993;18917-18923.
62. Kramer M.D., Reinartz J., Brunner G., Schirrmacher V. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis. 14:1994;210-222.
63. Heiden M., Seitz R., Egbring R. The role of inflammatory cells and their proteases in extravascular fibrinolysis. Semin. Thromb. Hemost. 22:1996;497-501.
64. Kitching A.R., Holdsworth S.R., Ploplis V.A., Plow E.F., Collen D., Carmeliet P., Tipping P.G. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J. Exp. Med. 185:1997;963-968.